Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of GT-02287 in Parkinson's disease, with participant recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• GT-02287

Snippet

Sponsor: Gain Therapeutics, Inc. | Conditions: Parkinson Disease | Phase 1 | Status: RECRUITING